- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Global Alliance for Improvement of HIV Diagnostics
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the African Society for Laboratory Medicine (ASLM) have joined with a number of global partners to launch the Diagnostics Access Initiative.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the African Society for Laboratory Medicine (ASLM) have joined with a number of global partners to launch the Diagnostics Access Initiative.
Partners in the Initiative, which calls for improving laboratory capacity so that all people living with HIV can be linked to effective HIV treatment services, include UNAIDS, the World Health Organization (WHO), the Clinton Health Access Initiative (CHAI), UNICEF, and the US President’s Emergency Plan for AIDS Relief (PEPFAR).
The initiative will advocate for greater funding for laboratory services and diagnostic tools and forge partnerships to close diagnostic access gaps.
For HIV treatment to be optimally effective, people accessing the treatment need to monitor their viral load frequently. Currently, very few high-burden countries routinely offer viral load testing. The Diagnostics Access Initiative will focus “urgent attention on the importance of developing new, affordable viral load and infant diagnosis technologies” said Dr. Tsehaynesh Messele, ASLM’s Chief Executive.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
